Jazz Pharmaceuticals(JAZZ) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Jeff Macdonald - Executive director & IRBruce Cozadd - Chairman and Chief Executive OfficerRenée Galá - President & COORobert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & DevelopmentPhilip Johnson - Executive VP & CFOJason Gerberry - MD & Equity ResearchMarc Goodman - Senior MD - NeuroscienceAnnabel Samimy - Managing DirectorAmy Li - SVP Equity ResearchAshwani Verma - Executive Dire ...
Jazz Pharmaceuticals(JAZZ) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals First Quarter twenty twenty five Webcast Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, Speaker1 there Speaker0 will be a question and answer session. Thank you. I would now like to ...
jamf(JAMF) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Jamf (JAMF) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Thank you for standing by, and welcome to JAMP's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for ...
INNOVATE (VATE) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Financial Data and Key Metrics Changes - Consolidated revenues for the first quarter of 2025 were $274.2 million, a decrease of 13% compared to $315.2 million in the prior year period [19] - Net loss attributable to common stockholders was $24.8 million or $1.89 per fully diluted share, compared to a net loss of $17.7 million or $2.21 per fully diluted share in the prior year [19] - Total adjusted EBITDA was $7.2 million, down from $12.8 million in the prior year period [19] Business Line Data and Key Metrics Changes - Infrastructure segment revenues decreased 14% to $264.9 million from $307.9 million in the prior year quarter, primarily due to project timing and size [20] - Life Sciences segment revenues increased 210% to $3.1 million from $1 million in the prior year quarter, driven by increased unit sales [22] - Spectrum segment revenues were $6.2 million, a slight decrease of $100,000 compared to the first quarter of 2024 [22] Market Data and Key Metrics Changes - DBM Global achieved revenues of $264.9 million and adjusted EBITDA of $16.7 million, with a gross margin improvement of approximately 110 basis points to 15.6% [7] - R2 tripled its year-over-year revenue to $3.1 million, with significant growth in North America [12] - The company is now serving 28 countries and has entered into distribution agreements in several European and South American countries [13] Company Strategy and Development Direction - The company is focused on addressing its capital structure and near-term debt maturities while leveraging valuable assets [6] - The strategic vision emphasizes maximizing the value of assets and exploring strategic alternatives [17] - The company is actively pursuing commercial opportunities in data casting and modernizing broadcasting capabilities [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on strategic objectives and highlighted the strong backlog and robust pipeline for DBM [6][7] - The ongoing tariff situation is being monitored, with no material impact observed on DBM's business as of now [8] - The company remains optimistic about the market opportunity for R2 and the momentum experienced year over year [15] Other Important Information - As of March 31, 2025, the company had total principal outstanding indebtedness of $672 million, an increase from the previous year [25] - Cash and cash equivalents were $33.3 million, down from $48.8 million at the end of 2024 [24] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded with management expressing satisfaction with the momentum to start the year [26][27]
Halozyme(HALO) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Halozyme Therapeutics (HALO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Bailey, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's First Quarter twenty twenty five Financial and Operating Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Please note this event is being recorded. I will now turn the ...
Grocery Outlet(GO) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Grocery Outlet (GO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Grocery Outlet's call to discuss financial results for the first quarter ended 03/28/2025. Speaking from management on today's call will be Jason Potter, president and chief executive officer and Chris Miller, chief financial officer. Following prepared remarks from Jason and Chris, we will open the call for questions. Please note that this conference call is being webcast live and a recording will be ...
Grand Canyon Education(LOPE) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Grand Canyon Education (LOPE) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Q1 twenty twenty five Grand Canyon Education Incorporated Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will Speaker1 then hear an automated message advising that you ...
Forrester Research(FORR) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Forrester Research (FORR) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for standing by. Welcome to Forrester's First Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Vice President of Corporate Development and Investor Relations, E ...
Energy Transfer(ET) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Energy Transfer (ET) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Thomas Long - Director & Co-CEOTheresa Chen - MD - Equity ResearchMackie McCrea - Director & Co-CEOJean Ann Salisbury - Managing DirectorSpiro Dounis - DirectorKeith Stanley - DirectorMichael Blum - Managing DirectorManav Gupta - Executive DirectorDylan Bramhall - Group Chief Financial Officer of LE GP, LLCJohn Mackay - VP - Equity ResearchGabriel Moreen - Managing Director Conference Call Participants Jeremy Tonet - Eq ...
Energy Transfer(ET) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Energy Transfer (ET) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Please note, today's event is being recorded. I would now like to turn the conference over to Tom Long. Please go ahead. Speaker1 Thank you, operator. Good afternoon, everyone, and welcome to the Energy Transfer first quarter twenty twenty five earnings call. Also joined today by Mackie McCree and other members of the senior management team who are here to help answer your questions after our prepared remarks. Hopefully, you saw th ...